Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spekulatius who wrote (6018)	3/24/2002 2:21:43 PM
From: Miljenko Zuanic	of 52153

<<Miljenko, does this mean that endostatin gets produced some where in the cascade of events leading to cancer growth?>> Cancer growth....Probably not. My layman view is that E is natural brake or control of the angiogenesis cascade. However, like Angio-1 and Angio-2, it may also have positive and negative effects on angiogenesis??? Depend on the other control mechanisms and cascades of the new vessel growth. Also, in tumor condition when angiogenesis is out of control seams that natural E can do very little to control or suppress further progression. Trials are using very large E doses. This increase problems with side effects, without definite positive therapeutic benefit. Bottom line I do not see E as true anti-angio candidate. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next